Effects of cell culture plastics on dendritic cells activated using Immunyr(TM)

肿瘤免疫治疗已成为肿瘤学中日益重要的治疗手段。它被定义为一种激活患者自身免疫系统以识别和应对正在发展的肿瘤的手段。 我们的目标是开发基于树突状细胞的癌症疫苗。树突状细胞是我们免疫系统的“守门人”，它们可以激活其他免疫细胞来攻击癌症。Kanyr Pharma公司开发了一种名为免疫(TM)的技术，该技术可以在重新注入患者之前改善培养中的树突状细胞的功能。Kanyr Pharma目前在没有完全封闭的塑料容器中生产这些树突状细胞。液体通过盖子和盖子手动引入容器中。对于临床生产树突状细胞，将细胞培养在封闭的塑料容器中会更安全，例如通过管子填充的袋子。使用封闭的细胞培养血管将有助于将基于树突状细胞的癌症疫苗转移到大多数大学医院，降低成本，确保为每个患者生产的自体树突状细胞的更高质量。该项目的主要目标是研究向封闭式塑料血管的过渡和不同塑料材料对在免疫(TM)化合物存在下获得的树突状细胞功能的影响。

Cancer immunotherapy has become an increasingly important therapeutic approach in oncology. It is defined as a means to activate a patient's own immune system to recognize and respond to a developing tumor. Our goal is to develop dendritic cell-based cancer vaccines. DCs are the "gatekeepers" of our immune system, and they can have the capacity to activate other immune cells to attack cancers. Kanyr Pharma has developed a technology called Immunyr(TM) that can improve the function of the dendritic cells in culture prior to reinjection into the patients. Kanyr Pharma currently produces these dendritic cells in plastic containers that are not completely closed. Liquids are introduced into the containers manually through caps and lids. For clinical production of the dendritic cells, it would be safer to culture the cells in closed plastic vessels such as bags filled through tubing. The use of closed cell culture vessels would help move dendritic cell based cancer vaccines into most university hospitals, reduce cost assure higher quality of the autologous dendritic cells produced for each patient. The main objective of this project is to study the effect of the transition to closed plastic vessels and different plastic materials on the function of dendritic cells obtained in the presence of Immunyr(TM) compounds.